WHO ICTRP trial
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with…
NL-OMON52935 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON52935 |
|---|---|
| Public title | A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer |
| Scientific title | A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer - MS200647_0005 (Intr@pid Lung 005) |
| Primary sponsor | Merck |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Australia;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea (the Republic of);Netherlands;Russian Federation ;Spain;Taiwan (Province of China);Turkey;United States of America |
| Conditions | lung cancer Non-small cell lung cancer;10038666;lung cancer;Non-small cell lung cancer |
| Interventions | The study intervention consists of 60 Gy of radiation therapy concurrent with standard chemotherapy plus M7824 in Arm 1 or placebo in Arm 2, followed by up to 26 doses of M7824 (Arm 1) or durvalumab (Arm 2). ;Concurrent… |
| Registration date | Aug 24, 2022 |
| Target size | 20 |
| Secondary IDs | 2018-003265-34;IND 124757;NL67816.056.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: